Efficacy of PSMA ligand PET-based radiotherapy for recurrent prostate cancer after radical prostatectomy and salvage radiotherapy

Table 4 Results of uni- and multivariate analyses for androgen deprivation therapy-free survival (ADT-FS)

	Univariate analysis	Multivariable analysis
	p value	p value	OR, (95% CI)
Initial T stage (≤T2 vs ≥ T3)	0.07
Initial N stage (N0 vs N1)	0.95
Initial PSA level in ng/ml (≤20 vs > 20)	0.26
PSA nadir after RP (≤0.07 ng/mL vs > 0,07 ng/mL)	0.05	0.20	2.02 (0.68–5.99)
Number of removed LN at RP (≤15 vs > 15)	0.31
Initial risk group (intermediate+high risk vs. very high risk)	0.02	0.10	2.58 (0.8–7.98)
PSA dt (≤6 months, > 6 months)	0.10
Radiotherapy type (CF-RT vs., SBRT)	0.73
No. of irradiated metastases (1 vs > 1)	0.51
Type of metastases (Lymph node vs bone)	0.12
RT dose (≤50 Gy vs > 50 Gy)	0.44

ADT androgen deprivation therapy, CF-RT conventionally fractionated radiotherapy type, dt doubling time, Gy Gray, LN lymph nodes, PSA prostate-specific antigen, RP radical prostatectomy, sRT salvage radiotherapy, SBRT stereotactic body radiation therapy, SIB simultaneous integrated boost

ISSN: 1471-2407